Literature DB >> 20517336

Hematology. Are macrophages the bad guys in Hodgkin lymphoma?

Volker Diehl1.   

Abstract

Prognostic models for patients with Hodgkin lymphoma are imperfect and do not allow a precise individualized therapy. A recent gene-expression profiling study, translated into a routine immunohistological test, identified genes of tumor-associated macrophages as being responsible for treatment outcome in patients with Hodgkin lymphoma. If this finding is confirmed by other investigators, it could be a major step towards personalized therapy for patients with Hodgkin lymphoma.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20517336     DOI： 10.1038/nrclinonc.2010.71

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  10 in total

1.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

Authors:  Martin Hutchings; Annika Loft; Mads Hansen; Lars Møller Pedersen; Thora Buhl; Jesper Jurlander; Simon Buus; Susanne Keiding; Francesco D'Amore; Anne-Marie Boesen; Anne Kiil Berthelsen; Lena Specht
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

Review 2.  The microenvironment in mature B-cell malignancies: a target for new treatment strategies.

Authors:  Jan A Burger; Paolo Ghia; Andreas Rosenwald; Federico Caligaris-Cappio
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

3.  Toward a personalized treatment of Hodgkin's disease.

Authors:  Vincent T DeVita; José Costa
Journal:  N Engl J Med       Date:  2010-03-11       Impact factor: 91.245

4.  Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.

Authors:  Christian Steidl; Tang Lee; Sohrab P Shah; Pedro Farinha; Guangming Han; Tarun Nayar; Allen Delaney; Steven J Jones; Javeed Iqbal; Dennis D Weisenburger; Martin A Bast; Andreas Rosenwald; Hans-Konrad Muller-Hermelink; Lisa M Rimsza; Elias Campo; Jan Delabie; Rita M Braziel; James R Cook; Ray R Tubbs; Elaine S Jaffe; Georg Lenz; Joseph M Connors; Louis M Staudt; Wing C Chan; Randy D Gascoyne
Journal:  N Engl J Med       Date:  2010-03-11       Impact factor: 91.245

Review 5.  Current strategies and new approaches in the treatment of Hodgkin's lymphoma.

Authors:  Michael Fuchs; Volker Diehl; Daniel Re
Journal:  Pathobiology       Date:  2006       Impact factor: 4.342

Review 6.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

7.  Gene expression profiling defines molecular subtypes of classical Hodgkin's disease.

Authors:  Elisabeth Devilard; François Bertucci; Pascal Trempat; Reda Bouabdallah; Béatrice Loriod; Aurélia Giaconia; Pierre Brousset; Samuel Granjeaud; Catherine Nguyen; Daniel Birnbaum; Françoise Birg; Remi Houlgatte; Luc Xerri
Journal:  Oncogene       Date:  2002-05-02       Impact factor: 9.867

8.  Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma.

Authors:  Abel Sánchez-Aguilera; Carlos Montalbán; Paloma de la Cueva; Lydia Sánchez-Verde; Manuel M Morente; Mónica García-Cosío; José García-Laraña; Carmen Bellas; Mariano Provencio; Vicens Romagosa; Alberto Fernández de Sevilla; Javier Menárguez; Pilar Sabín; María J Mestre; Miguel Méndez; Manuel F Fresno; Concepción Nicolás; Miguel A Piris; Juan F García
Journal:  Blood       Date:  2006-03-21       Impact factor: 22.113

9.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

Authors:  D Hasenclever; V Diehl
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

10.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.

Authors:  Sandeep S Dave; George Wright; Bruce Tan; Andreas Rosenwald; Randy D Gascoyne; Wing C Chan; Richard I Fisher; Rita M Braziel; Lisa M Rimsza; Thomas M Grogan; Thomas P Miller; Michael LeBlanc; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Joseph M Connors; Peter M Lansdorp; Qin Ouyang; T Andrew Lister; Andrew J Davies; Andrew J Norton; H Konrad Muller-Hermelink; German Ott; Elias Campo; Emilio Montserrat; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Liming Yang; John Powell; Hong Zhao; Neta Goldschmidt; Michael Chiorazzi; Louis M Staudt
Journal:  N Engl J Med       Date:  2004-11-18       Impact factor: 91.245
  10 in total
  5 in total

1.  Interim PET in lymphoma: a step towards standardization.

Authors:  Michel Meignan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-10       Impact factor: 9.236

Review 2.  [Tumor-associated macrophages: Function and differentiation].

Authors:  G Niedobitek; M H Barros; J H Dreyer; F Hauck; D Al-Sheikhyaqoob
Journal:  Pathologe       Date:  2015-09       Impact factor: 1.011

3.  Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma.

Authors:  D Azambuja; Y Natkunam; I Biasoli; I S Lossos; M W Anderson; J C Morais; N Spector
Journal:  Ann Oncol       Date:  2011-05-20       Impact factor: 32.976

4.  Macrophage polarization reflects T cell composition of tumor microenvironment in pediatric classical Hodgkin lymphoma and has impact on survival.

Authors:  Mário H M Barros; Priscilla Segges; Gabriela Vera-Lozada; Rocio Hassan; Gerald Niedobitek
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

Review 5.  The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies - A Narrative Review.

Authors:  Paulina Stefaniuk; Agnieszka Szymczyk; Monika Podhorecka
Journal:  Cancer Manag Res       Date:  2020-04-29       Impact factor: 3.989
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.